Upload File

Download - Heregulin 50 ng/ml

Transcript
Page 1: Heregulin 50 ng/ml

Heregulin 50 ng/ml

Heregulin + Lap

Supplementary Fig. 3

Lapatinib - +

0

20

40

60

80

100

120

Inv

ad

ed

ce

lls

co

mp

are

d

to c

on

tro

l (%

)

SCR heregulin 50 ng/ml

Si-FASN + heregulin 50 ng/ml

(B)

Inv

ad

ed

ce

lls

co

mp

are

d

to S

CR

co

ntr

ol

(%)

0

20

40

60

80

100

120

SCR si-FASN

Heregulin 50 ng/ml

Heregulin + C75

(C)

C75 - +

0

20

40

60

80

100

120

Inv

ad

ed

ce

lls

co

mp

are

d

to c

on

tro

l (%

)

(A)

Top Related

Applications - Eppendorf · buffer). The wells thus contained the following final DNA concentrations: 25 ng/ml, 10 ng/ml, 2.5 ng/ml, 500 pg/ml, Results and Discussion Based on the
Applications - Eppendorf · buffer). The wells thus contained the following final DNA concentrations: 25 ng/ml, 10 ng/ml, 2.5 ng/ml, 500 pg/ml, Results and Discussion Based on the
The complement cascade - AbcamComplement C3a des Arg Hu Competitive Plasma 0.12 ng/ml 20 - 0.313 ng/ml ab133037 Complement C4 Hu Sandwich Serum, Plasma 0.3 µg/ml 5 - 0.313 µg/ml
The complement cascade - AbcamComplement C3a des Arg Hu Competitive Plasma 0.12 ng/ml 20 - 0.313 ng/ml ab133037 Complement C4 Hu Sandwich Serum, Plasma 0.3 µg/ml 5 - 0.313 µg/ml
Oral Fluid Drug Screen Device - Andatechdocuments.andatech.com.au/manuals/oratect-iii-saliva-drug-testing-k… · Diazepam 25 ng/ml 40 ng/ml 20 ng/ml 25 ng/ml 10 ng/ml 5 ng/ml 1
Oral Fluid Drug Screen Device - Andatechdocuments.andatech.com.au/manuals/oratect-iii-saliva-drug-testing-k… · Diazepam 25 ng/ml 40 ng/ml 20 ng/ml 25 ng/ml 10 ng/ml 5 ng/ml 1
ACPP: ANSELL CYTOSTATIC PERMEATION PROGRAM 13 Vinorelbine Navelbine Pierre Fabre LCMS/MS 10 mg/ml 6,48 ng/ml 43,72 ng/ml. SURGICAL GLOVES GAMMEX® Non-Latex GAMMEX® Latex GAMMEX®
ACPP: ANSELL CYTOSTATIC PERMEATION PROGRAM 13 Vinorelbine Navelbine Pierre Fabre LCMS/MS 10 mg/ml 6,48 ng/ml 43,72 ng/ml. SURGICAL GLOVES GAMMEX® Non-Latex GAMMEX® Latex GAMMEX®
Inclisiran and the ORION programme · Total AMG 145 (evolocumab) Free PCSK9 Free PCSK9 concentration (ng/mL) Free evolocumab concentration (ng/mL x 0.01) LDL-C Stein EA & RaalFJ Annu
Inclisiran and the ORION programme · Total AMG 145 (evolocumab) Free PCSK9 Free PCSK9 concentration (ng/mL) Free evolocumab concentration (ng/mL x 0.01) LDL-C Stein EA & RaalFJ Annu
Supplemental Information ...cat#15070-063), 10 ng/mL heregulin-1b (Peprotech, cat#100-03) and 10 ng/mL activin A (R&D Systems, cat#338-AC). Cells were plated at 50,000 or 33,000 cells/cm2
Supplemental Information ...cat#15070-063), 10 ng/mL heregulin-1b (Peprotech, cat#100-03) and 10 ng/mL activin A (R&D Systems, cat#338-AC). Cells were plated at 50,000 or 33,000 cells/cm2
Elevated Serum Creatine Kinase BB Levels in Patients with ... · serum CK-BB (>10 ng/ml) [range, 11 to 522 ng/ml; median, 40.0 ng/ml; mean, 76.0 ±19.2 (S.E.)]. Only 1 of 42 patients
Elevated Serum Creatine Kinase BB Levels in Patients with ... · serum CK-BB (>10 ng/ml) [range, 11 to 522 ng/ml; median, 40.0 ng/ml; mean, 76.0 ±19.2 (S.E.)]. Only 1 of 42 patients
Ganglioside GM1 theTrk receptor - PNAScontrol, 0; NGF(1 ng/ml), 1 ± 0.3; NGF(50ng/ml), 33 ± 2.7; NGF(1 ng/ml) +GM1,46 + 3.1; NGF(50ng/ml) +GM1,78 ±4.3; andGM1 alone, 0 (mean ±
Ganglioside GM1 theTrk receptor - PNAScontrol, 0; NGF(1 ng/ml), 1 ± 0.3; NGF(50ng/ml), 33 ± 2.7; NGF(1 ng/ml) +GM1,46 + 3.1; NGF(50ng/ml) +GM1,78 ±4.3; andGM1 alone, 0 (mean ±